ACTIA Investors

KEY ANNUAL FIGURES FROM 2012 TO 2021

Balance sheet assets…

In EUR millions20212020201920182017*201720162015201420132012
Goodwill24.1524.1524.1524.1524.5324.5321.6721.6721.7921.7921.79
Non-current assets179.90190.28194.42161.70130.98117.83110.33104.0095.7392.5190.53
Current assets404.23366.42372.37354.17298.29296.77252.79234.39208.78181.18167.74
Inventory172.66149.56161.13136.05108.90107.3793.7890.7376.7073.6271.77
Receivables144.74141.36140.22150.26125.06125.06118.38109.3297.0781.9676.30
Other receivables and cash86.8375.4971.0167.8664.3364.3340.6434.3435.0125.6019.67

* figures restated for IFRS 15

Balance sheet liabilities…

In EUR millions20212020201920182017*201720162015201420132012
Shareholders’equity113.58116.08140.38132.82127.45127.45125.24111.0095.0281.1172.16
Financial liabilities278.45256.22240.53205.60157.64157.64121.97121.03106.9398.4499.88
Total liabilities and shareholders’ equity598.30556.70566.79515.87429.27414.60363.12338.39304.51273.69258.27

 * figures restated for IFRS 15

Income statement…

In EUR millions20212020201920182017*201720162015201420132012
Sales462.84438.59520.41476.52433.32436.13431.65381.21339.89303.66289.11
Payroll charges131.60119.95123.13110.19102.85107.42103.8294.8088.1184.2482.72
Operating profit-9.92-6.8516.279.5819.8019.8026.3619.7521.3516.4310.37
Net income-6.07-19.448.729.198.518.5121.2816.1615.1310.924.13

* figures restated for IFRS 15

Other indicators…

In EUR millions20212020201920182017*201720162015201420132012
Staff3 6853 7183 8543 6973 4593 4593 2683 0672 7622 6802 768
Research & development80.1675.9683.1980.9866.9566.9556.8052.5248.0745.3646.35
EBITDA excl. hedging instrument **22.1424.2045.7529.5037.63 35.6342.54 33.00 33.66 26.38 19.87 

* figures restated for IFRS 15

** Net income+taxation+impairment of goodwill+interest and finance costs+depreciation charge

Ratios…

Percentage20212020201920182017*201720162015201420132012
Payroll charges /sales28%27%24%23%24%25%24%25%26%28%29%
Net income / sales-1%-4%2%2%2%2%5%4%4%4%1%
Net income / shareholders’ equity-5%-17%6%7%7%7%17%15%16%13%6%
Research & development / sales17%17%16%17%15%15%13%14%14%15%16%